A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden (Alternative-C)
The Alternative-C Trial is a prospective, multicenter Phase 2 Study to evaluate the efficacy
of the chemotherapy-free combination of copanlisib and obinutuzumab in patients with
previously untreated follicular lymphoma (FL) and a high tumor burden. Additionally, the
combination should be evaluated in terms of secondary efficacy endpoints, treatment
compliance, safety and patient-reported symptoms. The study Population includes Patients > 18
years of age with histologically confirmed follicular lymphoma grade 1, 2 or 3A with Ann
Arbor Stage III/IV or stage II not suitable for radiotherapy and in need of therapy.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.